《Journal Of Hematology & Oncology》雜志的最新年發文量為70篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章,以保持其在血液學領域的學術影響力。
該刊聚焦于醫學-血液學領域的前沿研究,致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 較慢,6-12周 。
Journal Of Hematology & Oncology 雜志發文統計
文章名稱引用次數
- Next generation of immune checkpoint therapy in cancer: new developments and challenges114
- The biology and role of CD44 in cancer progression: therapeutic implications107
- Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications87
- A phase open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma84
- Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy75
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel74
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics72
- Targeting mTOR for cancer therapy64
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitors63
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy49
國家/地區發文量
- CHINA MAINLAND287
- USA163
- Italy40
- France27
- GERMANY (FED REP GER)27
- Spain19
- Canada13
- Israel12
- South Korea11
- England10